Virchows Arch. 2017 Jul 14. doi: 10.1007/s00428-017-2184-1. [Epub ahead of print]
Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer.
Adjuvant chemotherapy; Hormone receptor positive invasive breast carcinoma; Nottingham Prognostic Index; Oncotype DX® Recurrence Score®; Risk assessment tools